AUTONOMIX MEDICAL, INC.: 10-Q filed 2026-02-11
What AUTONOMIX MEDICAL, INC. reported in its quarterly report filed 2026-02-11 (fiscal Q3 2026): 30 published measures, 94 facts as tagged in accession 0001437749-26-003816.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2026-02-11
- Fiscal period
- fiscal Q3 2026
- Accession
- 0001437749-26-003816 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AUTONOMIX MEDICAL, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 10,211,000 | USD | |
| At 2025-03-31 | 9,806,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 1,650,000 | USD | |
| At 2025-03-31 | 1,707,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 8,561,000 | USD | |
| At 2025-09-30 | 6,446,000 | USD | |
| At 2025-06-30 | 7,032,000 | USD | |
| At 2025-03-31 | 8,099,000 | USD | |
| At 2024-12-31 | 9,707,000 | USD | |
| At 2024-09-30 | 3,028,000 | USD | |
| At 2024-06-30 | 5,289,000 | USD | |
| At 2024-03-31 | 7,628,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 9,934,000 | USD | |
| At 2025-03-31 | 9,136,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | -3,261,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | -14,049,000 | USD | 275 |
| 2025-07-01 to 2025-09-30 | -7,450,000 | USD | 92 |
| 2025-04-01 to 2025-06-30 | -3,337,000 | USD | 91 |
| 2024-10-01 to 2024-12-31 | -2,712,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | -8,219,000 | USD | 275 |
| 2024-07-01 to 2024-09-30 | -2,807,000 | USD | 92 |
| 2024-04-01 to 2024-06-30 | -2,699,000 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-12-31 | -9,390,000 | USD | 275 |
| 2024-04-01 to 2024-12-31 | -5,749,000 | USD | 275 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-12-31 | 7,000 | USD | 275 |
| 2024-04-01 to 2024-12-31 | 10,000 | USD | 275 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 0 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 0 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 0 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 0 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-12-31 | 10,195,000 | USD | 275 |
| 2024-04-01 to 2024-12-31 | 8,974,000 | USD | 275 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-12-31 | -7,000 | USD | 275 |
| 2024-04-01 to 2024-12-31 | -10,000 | USD | 275 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | -64,427,000 | USD | |
| At 2025-03-31 | -50,379,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 8,955,809 | shares | 92 |
| 2025-04-01 to 2025-12-31 | 5,835,213 | shares | 275 |
| 2024-10-01 to 2024-12-31 | 1,851,910 | shares | 92 |
| 2024-04-01 to 2024-12-31 | 1,437,982 | shares | 275 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | -0.36 | USD/shares | 92 |
| 2025-04-01 to 2025-12-31 | -2.41 | USD/shares | 275 |
| 2024-10-01 to 2024-12-31 | -1.46 | USD/shares | 92 |
| 2024-04-01 to 2024-12-31 | -5.72 | USD/shares | 275 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 0 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 0 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 0 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 0 | USD | 275 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 20,000 | USD | |
| At 2025-03-31 | 21,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-12-31 | 528,000 | USD | 275 |
| 2024-04-01 to 2024-12-31 | 1,223,000 | USD | 275 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | -3,343,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | -14,297,000 | USD | 275 |
| 2024-10-01 to 2024-12-31 | -2,747,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | -8,336,000 | USD | 275 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 10,191,000 | USD | |
| At 2025-03-31 | 9,609,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 1,650,000 | USD | |
| At 2025-03-31 | 1,707,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 714,000 | USD | |
| At 2025-03-31 | 676,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 3,343,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 14,297,000 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 2,747,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 8,336,000 | USD | 275 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 1,724,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 5,684,000 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 1,044,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 3,172,000 | USD | 275 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 11,409,344 | shares | |
| At 2025-03-31 | 2,497,033 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 72,977,000 | USD | |
| At 2025-03-31 | 58,476,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-12-31 | 936,000 | USD | |
| At 2025-03-31 | 1,031,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | -3,261,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | -14,049,000 | USD | 275 |
| 2024-10-01 to 2024-12-31 | -2,712,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | -8,219,000 | USD | 275 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 1,619,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 8,613,000 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 1,703,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 5,164,000 | USD | 275 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-04-01 to 2025-12-31 | 9,000 | USD | 275 |
| 2024-04-01 to 2024-12-31 | 135,000 | USD | 275 |
Nonoperating interest expense
Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 0 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 0 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 45,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 130,000 | USD | 275 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-10-01 to 2025-12-31 | 82,000 | USD | 92 |
| 2025-04-01 to 2025-12-31 | 248,000 | USD | 275 |
| 2024-10-01 to 2024-12-31 | 35,000 | USD | 92 |
| 2024-04-01 to 2024-12-31 | 117,000 | USD | 275 |
Inspect the source
- Entity
- AUTONOMIX MEDICAL, INC. / CIK 0001617867
- Captured
- 2026-09-21T17:20:36.779Z
- SEC response SHA-256
83443c97b45957d71f1d4a611a7fde5ecae2c73201a2da6de7a3deb7c060a7d6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001617867.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))